Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma, a biopharmaceutical company focused on innovative oncology treatments, announced that CEO Ron Bentsur will present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City. The conference is scheduled for May 2, 2022, at 12:00 PM Eastern Time. Nuvectis is advancing two drug candidates: NXP800, for platinum-resistant, ARID1a-mutated ovarian carcinoma, which has received FDA Fast Track Designation, and NXP900, a SRC/YES1 kinase inhibitor with a pending IND application.

The company's commitment to addressing unmet medical needs in oncology highlights the significance of their innovative approaches in developing precision medicines.

Nuvectis Pharma (NASDAQ: NVCT) announced promising results for NXP800, demonstrating significant antitumor activity in cholangiocarcinoma through two patient-derived xenograft (PDX) models, as presented at the AACR Annual Meeting 2023.

Cholangiocarcinoma, with about 10,000 new cases annually in the U.S., has limited treatment options, with only 30% of patients eligible for surgical resection. Ron Bentsur, CEO, emphasized the urgent need for new therapies in this area, stating that NXP800's data offers hope for improved outcomes.

The research, led by Mayo Clinic's Dr. Rory L. Smoot, indicates potential clinical benefits from NXP800 for this challenging condition, which typically results in poor patient prognosis.

Nuvectis Pharma has initiated a Phase 1b clinical trial for NXP800, targeting patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. This trial, building on promising preclinical and Phase 1a results, will study the drug's safety and efficacy in this specific cancer population. The trial aims to enroll around 50 patients across multiple sites in the U.S., UK, and Europe. NXP800 is an oral small molecule that has shown strong anti-tumor activity in preclinical models and received Fast Track Designation by the FDA. Results from the previous Phase 1a study indicated acceptable safety with the most common side effects being manageable. The company anticipates sharing detailed results from Phase 1a at a future scientific conference.

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, announced upcoming presentations for its drug candidates NXP800 and NXP900 at the 2023 American Association for Cancer Research Meeting, scheduled from April 14-19 in Orlando, Florida. NXP800, currently in a Phase 1a study, targets advanced solid tumors and has received Fast Track Designation from the FDA for ARID1a-mutated ovarian carcinoma. NXP900 is a novel SRC/YES1 kinase inhibitor with an IND pending submission. Presentations will include significant findings on therapeutic efficacy in various cancer models.

FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, a biopharmaceutical firm specializing in precision oncology medicines, announced that CEO Ron Bentsur will join a fireside chat at the 35th Annual Roth Conference on March 14, 2023, at 12:00 PM PT (3:00 PM ET). Nuvectis is developing innovative treatments, including NXP800, currently in a Phase 1a trial for advanced solid tumors and has received Fast Track Designation from the FDA for treating platinum-resistant ovarian carcinoma. Another candidate, NXP900, is pending IND submission.

For more details, visit www.nuvectis.com.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported significant advancements in 2022, highlighted by FDA's Fast Track Designation for NXP800 aimed at treating ARID1A-mutated ovarian carcinoma. The ENOT and GOG Foundation will spearhead the Phase 1b clinical trial for NXP800. Additionally, the IND submission and Phase 1 study for NXP900 are anticipated in the first half of 2023. Financially, the company ended 2022 with $20 million in cash and an increased net loss of $19.1 million, reflecting rising R&D costs at $13.2 million. Nuvectis remains optimistic about its programs, emphasizing the year as potentially transformational for its drug candidates.

Nuvectis Pharma (NASDAQ: NVCT) announced promising results for its drug candidate NXP800 at the ESMO Gynecological Cancers Congress. In two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, NXP800 demonstrated significant tumor growth inhibition (TGI) of 70% and 82%, outperforming cisplatin's TGI of 42% and 20%, respectively.

Dr. Susana Banerjee highlighted the urgent need for new therapies for ovarian cancer patients, particularly those with ARID1a mutations, which are linked to poor outcomes. NXP800 is set to enter a Phase 1b clinical trial, following its Fast Track Designation from the FDA for treating platinum-resistant ovarian carcinoma.